4 research outputs found
PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study
Background: A recently developed haemostatic peptide gel for endoscopic application has been introduced to improve the management of gastrointestinal bleeding. The aim of this pilot study was to evaluate the feasibility, safety, efficacy and indication profiles of PuraStat in a clinical setting.
Methods: In this prospective observational multicentre pilot study, patients with acute non-variceal gastrointestinal bleeding (upper and lower) were included. Primary and secondary application of PuraStat was evaluated. Haemoglobin, prothrombin time, platelets and transfusion behaviour were documented before and after haemostasis. The efficacy of PuraStat was assessed during the procedure, at 3 days and 1 week after application.
Results: 111 patients with acute gastrointestinal bleeding were recruited into the study. 70 percent (78/111) of the patients had upper gastrointestinal bleeding and 30% (33/111) had lower gastrointestinal bleeding. After primary application of PuraStat, initial haemostatic success was achieved in 94% of patients (74/79, 95% CI 88-99%), and in 75% of the patients when used as a secondary haemostatic product, following failure of established techniques (24/32, 95% CI 59-91%). The therapeutic success rates (absence of rebleeding) after 3 and 7 days were 91% and 87% after primary use, and 87% and 81% in all study patients. Overall rebleeding rate at 30 day follow-up was 16% (18/111). In the 5 patients who finally required surgery (4.5%), PuraStat allowed temporary haemostasis and stabilisation.
Conclusions: PuraStat expanded the therapeutic toolbox available for an effective treatment of gastrointestinal bleeding sources. It could be safely applied and administered without complications as a primary or secondary therapy. PuraStat may additionally serve as a bridge to surgery in order to achieve temporary haemostasis in case of refractory severe bleeding, possibly playing a role in preventing immediate emergency surgery
Antibody-Mediated Status Epilepticus: A Retrospective Multicenter Survey
Background: In recent years, an increasing number of autoantibodies
(AB) have been detected in the CSF and serum of
patients with new onset epilepsy. Some of these patients develop
convulsive or nonconvulsive status epilepticus (ABSE),
necessitating intensive medical care and administration
of multiple antiepileptic and immunomodulatory treatments
of uncertain effectiveness. Objectives: In this retrospective
multicenter survey we aimed to determine the
spectrum of gravity, the duration and the prognosis of the
disorder. In addition, we sought to identify the antibodies
associated with this condition, as well as determine whether
there is a most effective treatment regime. Methods: 12 European
Neurology University Clinics, with extensive experience
in the treatment of SE patients, were sent a detailed questionnaire regarding symptoms and treatment of AB-SE
patients. Seven centers responded positively, providing a total
of 13 patients above the age of 16. Results: AB-SE affects
mainly women (12/13, 92%) with a variable age at onset (17–
69 years, median: 25 years). The duration of the disease is also
variable (10 days to 12 years, median: 2 months). Only the 3
oldest patients died (55–69 years). Most patients were diagnosed
with anti NMDAR encephalitis (8/13) and had oligoclonal
bands in the CSF (9/13). No specific treatment regimen
(antiepileptic, immunomodulatory) was found to be clearly
superior. Most of the surviving 10 patients (77%) recovered
completely or nearly so within 2 years of index poststatus.
Conclusion: AB-SE is a severe but potentially reversible condition.
Long duration does not seem to imply fatal outcome;
however, age older than 50 years at time of onset appears to
be a risk factor for death. There was no evidence for an optimal
antiepileptic or immunomodulatory treatment. A prospective
multicenter study is warranted in order to stratify
the optimal treatment algorithm, determine clear risk factors of unfavorable outcome and long-term prognosis
Antibody-mediated status epilepticus: a retrospective multicenter survey
Background: In recent years, an increasing number of auto-antibodies (AB) have been detected in the CSF and serum of patients with new onset epilepsy. Some of these patients develop convulsive or nonconvulsive status epilepticus (AB-SE), necessitating intensive medical care and administration of multiple antiepileptic and immunomodulatory treatments of uncertain effectiveness. Objectives: In this retrospective multicenter survey we aimed to determine the spectrum of gravity, the duration and the prognosis of the disorder. In addition, we sought to identify the antibodies associated with this condition, as well as determine whether there is a most effective treatment regime. Methods: 12 European Neurology University Clinics, with extensive experience in the treatment of SE patients, were sent a detailed questionnaire regarding symptoms and treatment of AB-SE patients. Seven centers responded positively, providing a total of 13 patients above the age of 16. Results: AB-SE affects mainly women (12/13, 92%) with a variable age at onset (17-69 years, median: 25 years). The duration of the disease is also variable (10 days to 12 years, median: 2 months). Only the 3 oldest patients died (55-69 years). Most patients were diagnosed with anti NMDAR encephalitis (8/13) and had oligoclonal bands in the CSF (9/13). No specific treatment regimen (antiepileptic, immunomodulatory) was found to be clearly superior. Most of the surviving 10 patients (77%) recovered completely or nearly so within 2 years of index poststatus. Conclusion: AB-SE is a severe but potentially reversible condition. Long duration does not seem to imply fatal outcome; however, age older than 50 years at time of onset appears to be a risk factor for death. There was no evidence for an optimal antiepileptic or immunomodulatory treatment. A prospective multicenter study is warranted in order to stratify the optimal treatment algorithm, determine clear risk factors of unfavorable outcome and long-term prognosis